Overview

A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors

Status:
RECRUITING
Trial end date:
2027-07-01
Target enrollment:
Participant gender:
Summary
A Phase 1 First-in-Human study of YL217 in Patients with Advanced Solid Tumors
Phase:
PHASE1
Details
Lead Sponsor:
MediLink Therapeutics (Suzhou) Co., Ltd.